Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Stock Information for Aclaris Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aclaris Therapeutics Inc.

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.